Cancer Vaccines

Cancer Vaccines

Global Cancer Vaccines Market to Reach US$14.8 Billion by 2030

The global market for Cancer Vaccines estimated at US$7.9 Billion in the year 2023, is expected to reach US$14.8 Billion by 2030, growing at a CAGR of 9.4% over the analysis period 2023-2030. Preventive Vaccine, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$7.6 Billion by the end of the analysis period. Growth in the Therapeutic Vaccine segment is estimated at 10.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.1 Billion While China is Forecast to Grow at 12.9% CAGR

The Cancer Vaccines market in the U.S. is estimated at US$2.1 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.1 Billion by the year 2030 trailing a CAGR of 12.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.1% and 8.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.5% CAGR.

Key Trends and Drivers

Cancer vaccines represent a significant advancement in oncological medicine, offering potential for both the prevention and treatment of various forms of cancer. These vaccines work by stimulating the immune system to attack cells that display tumor-specific antigens, thereby preventing these cells from developing into full-blown cancers or eradicating existing tumors. Preventative vaccines, such as those developed for human papillomavirus (HPV) which is linked to cervical, anal, and other cancers, have already demonstrated efficacy in reducing cancer risk among vaccinated populations. Therapeutic cancer vaccines, on the other hand, are used to treat existing cancers by strengthening the body`s immune response to fight the cancer cells. Several therapeutic vaccines are in clinical trials, targeting a range of cancers including melanoma, prostate, lung, and breast cancers.

The development and enhancement of cancer vaccines involve intricate biotechnological advancements and significant research investments. Molecular techniques such as gene sequencing and bioinformatics are crucial in identifying tumor-specific antigens and developing vaccines that can target them effectively. Modern biotechnology has also enabled the design of personalized vaccines that are tailored to the unique genetic makeup of an individual’s tumor, thereby increasing the effectiveness of the treatment. Furthermore, innovations such as the use of viral vectors, dendritic cell vaccines, and RNA technology have expanded the potential of therapeutic cancer vaccines. These advances have been supported by a robust clinical trial infrastructure that allows for the rapid assessment and optimization of vaccine formulations and dosing schedules, ensuring that only the most effective treatments reach patients.

The growth in the cancer vaccine market is driven by several factors, including the increasing incidence of cancer worldwide, the rising demand for personalized medicine, and substantial investments in healthcare infrastructure supporting immunotherapy. As cancer remains a leading cause of death globally, governments and healthcare organizations are emphasizing early detection and prevention, which bolsters the market for preventive vaccines. In parallel, the therapeutic cancer vaccine sector benefits from the growing number of cancer patients who require effective treatment after diagnosis. Technological advancements in vaccine development platforms and adjuvant systems continue to enhance the efficacy and safety profiles of cancer vaccines, making them more appealing to both healthcare providers and patients. Additionally, the growing public awareness about the potential of immunotherapy in treating cancer, coupled with increasing healthcare spending in emerging economies, is propelling market growth. Market expansion is further supported by strategic collaborations between biopharmaceutical companies aiming to accelerate the development and commercialization of new vaccines. These drivers ensure the sustained growth of the cancer vaccine industry, reflecting its critical role in modern oncological therapeutics and preventive healthcare.

Select Competitors (Total 61 Featured) -

• Agenus Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Celldex Therapeutics Inc.
• F. Hoffmann-La Roche Ltd
• Genexine Inc.
• Gritstone bio
• ImmunityBio, Inc.
• Immutep Ltd
• ISA Pharmaceuticals B.V.
• Merck & Co. Inc.
• Northwest Biotherapeutics Inc.
• OncBioMune Pharmaceuticals Inc.
• Oncovir Inc.
• Pfizer Inc.
• Sanofi SA
• Serum Institute of India Pvt. Ltd.;

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.